---
title: "Clearmind amends convertible note deal, leaving $10 million available"
url: "https://aibio.space/news/clearmind-amends-convertible-note-deal-leaving-10-million-available/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-04-30"
section: "Debt Financing"
tickers: "NASDAQ:CMND"
source: "https://www.sec.gov/Archives/edgar/data/1892500/000121390026050241/ea0288483-6k_clearmind.htm"
summary: "The amendment raises the subscription amount so that $10,000,000 of capacity remains for future convertible promissory notes."
---

By the aibio.space news desk.

Sources

- [Clearmind Medicine Form 6-K](https://www.sec.gov/Archives/edgar/data/1892500/000121390026050241/ea0288483-6k_clearmind.htm)

[CMND](https://aibio.space/companies/clearmind-medicine/)

2026-04-30

# Clearmind amends convertible note deal, leaving $10 million available

Tickers [CMND](https://aibio.space/companies/clearmind-medicine/)

The amendment raises the subscription amount so that $10,000,000 of capacity remains for future convertible promissory notes.

## Key facts

- **Company**: Clearmind Medicine Inc. (NASDAQ: CMND)

- **News type**: Debt Financing

- **Primary source**: [Clearmind Medicine Form 6-K](https://www.sec.gov/Archives/edgar/data/1892500/000121390026050241/ea0288483-6k_clearmind.htm)

*A boardroom table with chairs and a laptop. CC0, via rawpixel. The picture shows the field, not the companies named.*

Clearmind Medicine Inc. said in a Form 6-K dated April 30, 2026 that it has amended its securities purchase agreements for convertible promissory notes. The company first entered into the agreements on September 17, 2025, with investors it calls the CLA Investors. It agreed to issue the notes from time to time, up to an aggregate principal amount of $10,000,000.

The April 30 amendment increased the Subscription Amount so that, as of that date, $10,000,000 of capacity remains available for future issuances of additional notes. The full amendment is filed as Exhibit 10.1.

The report does not give the interest rate, maturity, conversion price or security for the notes, and it does not say what Clearmind will use the money for. The filing does not name the CLA Investors and names no placement agent or advisor.

In the same report, Clearmind said its chairman, Amitay Weiss, stepped down from the board on April 26, 2026, and that the board appointed Hila Kiron-Revach as chairperson on April 27, 2026. The company said his resignation was not due to any disagreement with the company.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

CMND

Clearmind Medicine Inc.

NASDAQ · Canada

Open the starter desk

## More in Debt Financing

Debt Financing

### [Pelthos amends Horizon venture loan, funds Loans E to H and adds Loans I and J](https://aibio.space/news/pelthos-amends-horizon-venture-loan-funds-loans-e-h-adds-loans/)

Oct 30, 2026

Debt Financing

### [Repligen announces $1.0 billion private convertible notes transaction](https://aibio.space/news/repligen-announces-1-0-billion-private-convertible-notes-transaction/)

Oct 30, 2026

Debt Financing

### [FOXO to buy Ludwig Enterprises preferred stock with majority voting power](https://aibio.space/news/foxo-buy-ludwig-enterprises-preferred-stock-majority-voting-power/)

Oct 29, 2026

---
Source page: https://aibio.space/news/clearmind-amends-convertible-note-deal-leaving-10-million-available/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Clearmind amends convertible note deal, leaving $10 million available", 2026-04-30, https://aibio.space/news/clearmind-amends-convertible-note-deal-leaving-10-million-available/